Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Alberta
$27,000.00
Validating ABO-Perfusion-A Enzyme Treatment Under Ex-Situ Heart Perfusion Conditions to Expand the Donor Pool for Pediatric Heart Transplantation
FY 2025-26
Summary
Pediatric patients with advanced heart disease continue to die on the transplant waitlist due to delays in finding a compatible donor heart. Blood-type mismatch remains one of the biggest barriers and numerous suitable donor hearts are declined only because they are not ABO compatible. A promising approach is a dual-enzyme system that removes A-antigen from donor tissues so the organ functions as type O, with encouraging results already shown in lungs and kidneys. Whether this treatment can work safely in whole human hearts has never been tested, and determining this is the goal of the proposed research.
To study this approach, the project will begin by testing the enzyme treatment on red blood cells and small blood vessels to confirm the best enzyme dose and time. Following, whole human donor hearts that are not suitable for transplantation will be tested under the same optimized conditions. These hearts can be kept working outside the body using a machine that gently pumps warm oxygen-rich fluid through the heart vessels. This would make it possible to observe the heart’s response in real-time. This setup also allows for the collection of small tissue samples throughout the process to determine whether the A blood-type marker is being removed and whether the heart remains healthy. Treated hearts will be compared with untreated hearts to see whether removing the A marker offers measurable protection. Monitoring how each heart responds can help estimate whether this approach could be suitable for future transplant use.
If successful, this work could increase the number of usable donor hearts for pediatric patients. This would help expand the donor pool, decrease waitlist mortality, and ultimately support more equitable access to lifesaving transplants.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572814
Name
Lam Adrien
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Validating ABO-Perfusion-A Enzyme Treatment Under Ex-Situ Heart Perfusion Conditions to Expand the Donor Pool for Pediatric Heart Transplantation
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
A-Antigen Enzymatic Removal; Abo-Incompatible Transplantation; Antibody-Mediated Rejection; Cardiovascular Physiology; Endothelial Glycobiology; Ex-Situ Heart Perfusion; Glycan Engineering; Organ Preservation; Pediatric Heart Transplantation; Transplant Immunology
Abstract
Pediatric patients with advanced heart disease continue to die on the transplant waitlist due to delays in finding a compatible donor heart. Blood-type mismatch remains one of the biggest barriers and numerous suitable donor hearts are declined only because they are not ABO compatible. A promising approach is a dual-enzyme system that removes A-antigen from donor tissues so the organ functions as type O, with encouraging results already shown in lungs and kidneys. Whether this treatment can work safely in whole human hearts has never been tested, and determining this is the goal of the proposed research.
To study this approach, the project will begin by testing the enzyme treatment on red blood cells and small blood vessels to confirm the best enzyme dose and time. Following, whole human donor hearts that are not suitable for transplantation will be tested under the same optimized conditions. These hearts can be kept working outside the body using a machine that gently pumps warm oxygen-rich fluid through the heart vessels. This would make it possible to observe the heart’s response in real-time. This setup also allows for the collection of small tissue samples throughout the process to determine whether the A blood-type marker is being removed and whether the heart remains healthy. Treated hearts will be compared with untreated hearts to see whether removing the A marker offers measurable protection. Monitoring how each heart responds can help estimate whether this approach could be suitable for future transplant use.
If successful, this work could increase the number of usable donor hearts for pediatric patients. This would help expand the donor pool, decrease waitlist mortality, and ultimately support more equitable access to lifesaving transplants.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lam, Adrien
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~